Annual reportSep 2026
Sep 2026 · Reg. 34 (1) Annual Report. 4 Sep - FY2025-26 annual report and 11th AGM notice issued; AGM scheduled for September 29, 2026.
Source: Bse
Innovana Thinklabs Limited (INNOVANA)
Small CapPharma stocks · Small cap · NSE
Innovana Thinklabs Limited operates in Pharma Services, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result13 Aug, 06:55 pm IST
Score22 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
56Neutralfull bear SMA stack · SMA20 -3.5% / mo · MACD + · near 52W low · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 26
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
INNOVANAD candles · FIT view-23.4%Latest close ₹290.65 on 2026-10-21
Bar
-2.1%
RSI
44
MACD hist
0.50
52W pos
5%
2026-10-21O ₹296.90H ₹301.80L ₹285.20C ₹290.65Vol 11,579 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
INNOVANANifty PharmaNifty 500
- INNOVANA
- -14.7%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- -8.2 pp
Chart stats
21 Oct 2026- From 52W high
- -44.6%
- 52W range position
- 5%
- ATR (14)
- 5.1%
- Volume vs 20D
- 0.37x
- Avg traded value
- ₹0.9 Cr
- 20D price channel
- ₹278.4 - ₹314.8
₹525
₹278.4 - ₹525
₹14.8
Latest completed session
20-session average
38.8% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · FAIR VALUE59
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad2
Revenue +21.4% · PAT -57.9% YoY
Technical
Neutral56
Price trend and sector-relative-strength timing.
Valuation
Legacy model+56.8%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence68
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 2/100PAT -58% YoY · margin compression · Rev +21% YoY · +20% QoQ
Filed 13 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹39 Cr | +21.4% | +19.5% |
| EBITDA | ₹6.9 Cr | -57.3% | +117.4% |
| Operating margin | 17.6% | -3248 bps | +794 bps |
| PAT | ₹5.5 Cr | -57.9% | +203.8% |
| PAT margin | 14.2% | -2670 bps | +861 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 20.30
- P/B
- 2.29
- EV/EBITDA
- 14.85
- Market Cap
- 625.00Cr
Profitability
- ROE
- 15.00%
- ROCE
- 15.80%
- ROA
- 7.97%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 19.00%
- EPS 5Y
- 19.00%
- Revenue 3Y
- 19.00%
- EPS 3Y
- 15.00%
Balance Sheet
- Debt/Equity
- 0.21
- Interest Coverage
- 7.20×
- Altman Z
- 6.07
- Book Value
- 132.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 4/5
- OCF
- 27.00 Cr
- EPS TTM
- 14.96
Shareholding
- Promoter Hold
- 72.65%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 9%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 132+28.2% vs prev
Net Profit
₹ CrLatest: 37.0-17.8% vs prev
Return on Equity
%Latest: 13.6-38.3% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 44.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~3.7% over last month) — short-term momentum negative.
- RSI(14) at 44 — falling, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & peers
U-Score 59 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 59 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Financial Turnaround
Fundamental score breakdown
U band · FAIR VALUEValuation14/30
Growth16/25
Quality9/20
Balance Sheet10/15
Cash Flow4/10
Piotroski
8/9 (+5)
Penalties
1
Raw sum
59
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
59/100 · legacy band FAIR VALUE
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 56.8%.
- Balance sheet contributes 10/15 to the score.
Main drags
- Cash flow is weaker at 4/10; verify the latest quarterly trend.
- Quality is weaker at 9/20; verify the latest quarterly trend.
- Valuation is weaker at 14/30; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
20.3
PB
2.3
EV/EBITDA
14.8
ROE
15.0%
ROCE
15.8%
FCF Yield
—
Debt/Equity
0.2
MoS
+56.8%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 22 Oct 2026
v4.3-runtime-valuation
Final score
59
Previous: 59
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
+56.8%
Previous: +56.8%
Score history
12 stored score snapshots. Latest stored move: +0 points.
22 Oct 2026
v4.3-runtime-valuation
59
59
59
59
59
59
59
59
59
59
59
59
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹210.79
-37.9% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹673.2
+56.8% MoS
PEG
1.17
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
WANBURY
Small
Wanbury Limited
Pharmaceuticals
match 139
69
11.2
68.4%
+74%
UNDERVALUED
AMANTA
Small
Amanta Healthcare Limited
Pharmaceuticals
match 137
39
48.2
10.3%
+6%
WATCHLIST
GLOTTIS
Small
Glottis Limited
Pharmaceuticals
match 136
29
13.9
13.4%
-75%
OVERVALUED
ALBERTDAVD
Small
Albert David Limited
Pharmaceuticals
match 135
27
21.7
-0.4%
-19%
OVERVALUED
ANUHPHR
Small
Anuh Pharma Limited
Pharmaceuticals
match 135
45
19.5
10.7%
+42%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Innovana Thinklabs Limited operates in Pharma Services, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
68Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 56th percentile of the scored universe and 43rd percentile within Pharma. Main check: results consistency is weak at 29/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
3 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
56th percentile
overall median 67 · Pharma: 43rd pctile, median 70 · Small: 60th pctile, median 66
Evidence depth
Financial-only
3 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
58
watch · capital discipline
Results
29
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 72.7%.
- ▸Promoter pledge is zero.
- ▸4 years of positive FCF.
- ▸4/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸2 latest quarters had PAT decline worse than 25% YoY.
- ▸ROCE trend is -8.3%.
- ▸1/4 latest quarters had positive YoY PAT growth.
- ▸OPM spread across recent quarters is 47.7%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Innovana Thinklabs Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Sep - A copy of he newspaper advertisement published in the English and Vernacular Language newspaper on September 05, 2026 regarding evoting information for 11th ....
Source: Bse
Annual reportSep 2026
Sep 2026 · Notice Convening The 11Th Annual General Meeting And Annual Report Of The Company For The F.Y 2025-26 4 Sep - FY2025-26 annual report and 11th AGM notice issued; AGM on September 29, 2026.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 14 Aug - Newspaper publication of financial results for the quarter ended June 30, 2026.
Source: Bse
AnnouncementMay 2026
May 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 22 May - The Newspaper Publication for Notice of Postal Ballot has been published in English and Vernacular newspaper on May 22, 2026. The copies of newspaper advertisements …
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Change in Directorate 20 May - Board approved FY26 audited results, unmodified audit opinion, and reappointed internal auditor and independent director.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
AnnouncementMar 2026
Mar 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 21 May - The Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Financial Year ended March 31, 2026 has been published in an …
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.